Inflammatory Bowel Disease
The main pathways involved in IBD include intestinal barrier dysfunction, mucus barrier impairment, dysbiosis-driven innate immune activation, and persistent cytokine-mediated inflammation. Key barrier components such as ZO-1, occludin, claudins, and MUC2 are commonly disrupted, increasing epithelial permeability and microbial translocation. This promotes activation of inflammatory hubs including TNF-α, NF-κB, IL-1β, IL-6/STAT3, and IL-23/Th17, while JAK/STAT signaling integrates multiple cytokine inputs that sustain chronic mucosal injury. Together, these pathways drive epithelial damage, immune dysregulation, and failure of mucosal healing in ulcerative colitis and Crohn’s disease
| Rank |
Pathway / Axis |
Representative Targets / Markers |
Typical Direction in IBD |
Main Relevance |
| 1 |
Intestinal Barrier Integrity / Tight Junctions |
ZO-1 (TJP1), Occludin (OCLN), Claudins (especially CLDN2, CLDN1) |
ZO-1 ↓, OCLN ↓, barrier loosened; CLDN2 often ↑ |
Core barrier failure increases intestinal permeability, microbial entry, and chronic inflammation |
| 2 |
Mucus Barrier / Goblet Cell Axis |
MUC2, goblet cells, antimicrobial peptides |
MUC2 and goblet protection often impaired |
Weak mucus defense exposes the epithelium to luminal bacteria and antigens |
| 3 |
TNF-α Inflammatory Axis |
TNF-α, TNFR1, TNFR2 |
↑ |
Major inflammatory driver and validated therapeutic target in IBD |
| 4 |
NF-κB Signaling |
NF-κB, IKK, IκB, COX-2, iNOS |
↑ |
Central transcriptional hub for cytokines, chemokines, and inflammatory amplification |
| 5 |
IL-23 / Th17 Axis |
IL-23, IL-23R, IL-17A, IL-22, RORγt |
↑ / dysregulated |
Important bridge between innate and adaptive immune inflammation |
| 6 |
JAK / STAT Signaling |
JAK1, JAK2, TYK2, STAT3 |
↑ / activated |
Integrates multiple cytokine signals that sustain mucosal inflammation |
| 7 |
IL-6 / STAT3 Axis |
IL-6, IL-6R, gp130, STAT3 |
↑ |
Supports inflammatory persistence, immune-cell survival, and epithelial injury signaling |
| 8 |
IL-1β / Inflammasome Axis |
IL-1β, NLRP3, ASC, caspase-1 |
↑ |
Promotes innate inflammation, cytokine escalation, and epithelial damage |
| 9 |
Microbiota / Dysbiosis / PRR Signaling |
Dysbiosis, TLRs, MyD88, LPS-related signaling |
Dysregulated / activated |
Links altered microbiota to barrier loss and immune activation |
| 10 |
Oxidative Stress / Redox Imbalance |
ROS, lipid peroxidation, MPO, antioxidant defenses |
↑ oxidative stress |
Contributes to epithelial injury, inflammatory signaling, and impaired healing |
| 11 |
Leukocyte Trafficking / Adhesion |
Integrins, MAdCAM-1, ICAM-1, VCAM-1, chemokines |
↑ |
Drives immune-cell recruitment into inflamed intestinal tissue |
| 12 |
Epithelial Apoptosis / Restitution / Mucosal Healing |
Caspases, repair pathways, epithelial proliferation and restitution markers |
Injury ↑, healing impaired |
Determines whether mucosal damage resolves or progresses to chronic disease |
| Rank |
Natural Product |
Best Fit in IBD |
Evidence Level |
Main Rationale |
Notes |
| 1 |
Curcumin |
Mainly Ulcerative Colitis (UC) |
Best human evidence |
Strongest overall adjunctive clinical support among common natural products for active UC |
Anti-inflammatory; NF-κB / cytokines / oxidative stress; mucosal support |
| 2 |
Indigo naturalis (Qing Dai) |
Mainly UC |
Strong efficacy, safety-limited |
Good human efficacy signals, but safety concerns lower practical rank |
Anti-colitic; immune/inflammatory modulation; use caution flag for safety |
| 3 |
Boswellia serrata |
UC / colitis |
Older smaller human trials |
Suggestive remission data and anti-inflammatory relevance, but evidence base is limited |
5-LOX / leukotrienes / inflammation / mucosal protection |
| 4 |
Aloe vera gel |
Mild-to-moderate UC |
Small human trial signal |
Some human improvement signal, though not as strong as curcumin or indigo naturalis |
Mucosal soothing / anti-inflammatory / healing support |
| 5 |
Andrographis paniculata / andrographolide |
Mostly UC |
Mixed human, stronger preclinical |
Mechanistically promising, but human benefit is less consistent |
NF-κB / cytokines / barrier and anti-inflammatory support |
| 6 |
Carvacrol |
Experimental colitis / dysbiosis / barrier dysfunction |
Preclinical |
Promising anti-colitis terpene with anti-inflammatory, antioxidant, and microbiota-related effects |
Dysbiosis / intestinal barrier integrity / NF-κB / oxidative stress |
| 7 |
Thymol |
Experimental colitis / barrier dysfunction |
Preclinical |
Promising anti-colitis terpene with cytokine suppression and NF-κB-related effects |
Dysbiosis / intestinal barrier integrity / NF-κB / COX-2 / oxidative stress |
| 8 |
Carvacrol + Thymol |
Experimental colitis, dysbiosis, bile-acid modulation |
Preclinical, mechanistically strong |
Combination may be especially relevant due to microbiota and bile-acid pathway effects in DSS colitis |
Bifidobacterium / secondary bile acids / barrier support / anti-colitic signaling |
| 9 |
Peppermint oil |
Supportive / experimental colitis / GI symptom relief |
Mainly preclinical for IBD; stronger IBS evidence |
Menthol-rich oil with anti-inflammatory, antispasmodic, and possible barrier-supportive effects, but limited direct human IBD evidence |
Menthol / TRP modulation / cytokines / oxidative stress / GI symptom support |
|